Top videos
Aspirin, or acetylsalicylic acid (ASA) is a salicylate drug, and is generally used as an analgesic (something that relieves pain without producing anesthesia or loss of consciousness) for minor aches and pains, to reduce fever (an antipyretic), and also as an anti-inflammatory drug.
Transvenous cardiac pace maker, also called endocardial pacing, is a potentially life saving intervention used primarily to correct profound bradycardia. It can be used to treat symptomatic bradycardias that do not respond to transcutaneous pacing or to drug therapy.
Overactive bladder syndrome is common. Symptoms include an urgent feeling to go to the toilet, going to the toilet frequently and sometimes leaking urine before you can get to the toilet (urge incontinence). Treatment with bladder training often cures the problem. Sometimes medication may be advised in addition to bladder training to relax the bladder.
Osteoporosis, which literally means porous bone, is a disease in which the density and quality of bone are reduced. As bones become more porous and fragile, the risk of fracture is greatly increased. The loss of bone occurs silently and progressively. Often there are no symptoms until the first fracture occurs.
Pelvic ureter. The ureter enters the pelvis, where it crosses anteriorly to the iliac vessels, which usually occurs at the bifurcation of the common iliac artery into the internal and external iliac arteries. Here, the ureters are within 5 cm of one another before they diverge laterally.
Fulminant hepatic failure (FHF) or acute liver failure (ALF) is defined as the rapid development of acute liver injury with severe impairment of the synthetic function and hepatic encephalopathy in a patient without obvious, previous liver disease.
A new report analyzing FDA-approved monoclonal antibodies (mAbs) produced by a select group of leading biotechnology companies shows that clinical development times – specifically the duration of Phase II and Phase III trials – are lengthening, while FDA review times have remained constant. The average time from investigational new drug (IND) filing to market was 6.7 years for 11 mABs approved between 1994 and 2003 but shot up to 8.3 years for 12 mAbs approved between 2004 and March 9, 2011, according to Deloitte Recap LLC’s analysis, Therapeutic Monoclonal Antibodies – Insights, Strategies and Data.
http://breatheasthmafree.blog300.com - Bronchitis Asthma Symptoms - Asthma Treatments For Adults
Asthma Sufferer?
Ex-Sufferer Reveals Own Natural
Remedy for Eliminating Asthma!...
http://breatheasthmafree.blog300.com
Bronchitis Asthma Symptoms - Asthma Treatments For Adults